Astellas Pharma US Inc. Pays $7.3 Million to Resolve False Claims Act Allegations Relating to Marketing of Drug Mycamine | Office of the Inspector General

Astellas Pharma US Inc. Pays $7.3 Million to Resolve False Claims Act Allegations Relating to Marketing of Drug Mycamine

Office Hours

Monday to Friday, 8:30 am to 5 pm,
except District holidays

Connect With Us

100 M Street, S.E.
Suite 1000
Washington, DC 20003

Phone: 202-727-2540
Fax: 202-727-9903
TTY: 711

Email Us

[email protected]

Ask The Inspector General